The Phase III ASTRO trial, presented at DDW 2025, confirmed that subcutaneous induction with Tremfya (guselkumab) is effective in moderate-to-severe UC. Patients receiving 400 mg SC at Weeks 0, 4, and 8 achieved Week 12 clinical remission in 36% versus 19% for placebo. Endoscopic improvement was observed in 44%, and symptomatic remission in over half of treated patients. These results were consistent with IV induction data, offering patients a more convenient alternative without compromising efficacy. Safety remained in line with previous findings. SC induction may improve adherence and reduce infusion-center reliance. Pending regulatory review, guselkumab may become the first IL-23 to offer both IV and SC induction options in UC.

Citation: https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-positioned-to-become-the-first-and-only-il-23-inhibitor-to-offer-subcutaneous-induction-in-ulcerative-colitis-as-demonstrated-in-new-data-through-24-weeks

Implication: SC induction could boost patient uptake and operational efficiency in UC treatment settings.